Review article: Medical treatment of moderate to severe Crohn's disease

Alimentary Pharmacology and Therapeutics, Supplement

Volumn 17, Issue 2, 2003, Pages 23-30

  Scribano, M ^a   Prantera, C ^a  

^a SAN CAMILLO FORLANINI HOSPITAL   (Italy)

Author keywords

[No Author keywords available]

Indexed keywords

ALICAFORSEN; ANTIBIOTIC AGENT; AZATHIOPRINE; BECLOMETASONE DIPROPIONATE; BUDESONIDE; CIPROFLOXACIN; CORTICOSTEROID; CYCLOSPORIN; ETANERCEPT; IMMUNOSUPPRESSIVE AGENT; INFLIXIMAB; MERCAPTOPURINE; METHOTREXATE; METRONIDAZOLE; NATALIZUMAB; RECOMBINANT INTERLEUKIN 10; RECOMBINANT INTERLEUKIN 11; THALIDOMIDE; TUMOR NECROSIS FACTOR ALPHA ANTIBODY;

ABDOMINAL PAIN; ALLERGIC PNEUMONITIS; CHRONIC DISEASE; CLINICAL TRIAL; CONFERENCE PAPER; CONTROLLED DRUG RELEASE; CROHN DISEASE; DEATH; DIARRHEA; DISEASE SEVERITY; DOSE RESPONSE; DROWSINESS; DRUG ACTIVITY; DRUG EFFECT; DRUG EFFICACY; DRUG HYPERSENSITIVITY; DRUG RESPONSE; DRUG SCREENING; EPIGASTRIC PAIN; FEVER; FRACTURE; HEADACHE; HEART FAILURE; HEART INFARCTION; HUMAN; INFECTION SENSITIVITY; INTESTINE MUCOSA; LEUKOPENIA; LIVER FIBROSIS; MAINTENANCE THERAPY; MALIGNANT NEOPLASTIC DISEASE; NAUSEA; NEUROTOXICITY; PERIPHERAL NEUROPATHY; PNEUMONIA; PRIORITY JOURNAL; REMISSION; SEPSIS; SIDE EFFECT; STOMATITIS; SYMPTOMATOLOGY; TASTE DISORDER; TREATMENT INDICATION; TREATMENT OUTCOME; TUBERCULOSIS; UPPER RESPIRATORY TRACT INFECTION; VOMITING;

ADRENAL CORTEX HORMONES; ANTI-BACTERIAL AGENTS; BIOLOGICAL PRODUCTS; CROHN DISEASE; HUMANS; IMMUNOSUPPRESSIVE AGENTS;

EID: 0037898157     PISSN: 09530673     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Conference Paper

References (59)

1. Summers RW, Switz DM, Session JT. National Cooperative Crohn's Disease Study (NCCDS): results of drug treatment. Gastroenterology 1979; 77: 847-69.
2. Malchow H, Ewe K, Brandes JW. European Cooperative Crohn's Disease Study (ECCDS): results of drug treatment. Gastroenterology 1984; 86: 249-66.
3. Greenberg G, Feagan B, Martin F, et al. Oral budesonide for active Crohn's disease. N Engl J Med 1994; 331: 836-41.
4. Rutgeers P, Lofboerg R, Malchow H, et al. A comparison of budesonide with prednisolone for active Crohn's disease. N Engl J Med 1994; 331: 842-5.
5. Gross V, Andus T, Caesar I. Oral pH-modified release budesonide versus 6-methylprednisolone in active Crohn's disease. Eur J Gastroenterol Hepatol 1996; 8: 905-10.
6. Campieri M, Ferguson A, Doe W, Persson T, Nilsson LG, and the Global Budesonide Study Group. Oral budesonide is as effective as oral prednisolone in active Crohn's disease. Gut 1997; 41: 209-14.
7. Ban-Meir S, Chowers Y, Lavy A, et al. Budesonide versus prednisone in the treatment of active Crohn's disease. Gastroenterology 1998; 115: 835-40.
8. Gross V, Caesar T, Andrus H, et al. Dose-finding study with oral budesonide in patients with active Crohn's ileocolitis. Gastroenterology 1997; 112: A986(Abstract).
9. Prantera C, Scribano ML, Berto E, Zannoni F. Antibiotic use in Crohn's disease. Why and how? Biodrugs 1997; 8: 293-306.
10. Prantera C, Scribano ML. Crohn's disease: the case for bacteria. Ital J Gastroenterol Hepatol 1999; 31: 244-6.
11. Ursing B, Kamme C. Metronidazole for Crohn's disease. Lancet 1975; i: 775-84.
12. Bernstein LH, Frank MS, Brandt LJ, et al. Healing of perianal Crohn's disease with metronidazole. Gastroenterology 1980; 79: 357-65.
13. Blichfeldt P, Blomhoff JP, Myhre E, Gjone E. Metronidazole in Crohn's disease: a double-blind cross-over clinical trial. Scand J Gastroenterol 1978; 13: 123-7.
14. Ursing B, Alm T, Barany F, et al. A comparative study of metronidazole and sulfasalazine for active Crohn's disease: the Cooperative Crohn's Disease Study in Sweden. II. Result. Gastroenterology 1982; 83: 550-62.
15. Ambrose NS, Allan RN, Keighley MRB, et al. Antibiotic therapy for treatment in relapse of intestinal Crohn's disease: a prospective randomized study. Dis Colon Rectum 1985; 28: 81-5.
16. Sutherland L, Singleton J, Sessions J, et al. Double-blind, placebo controlled trial of metronidazole in Crohn's disease. Gut 1991; 32: 1071-5.
17. Brandt LJ, Bernstein LH, Boley SS, et al. Metronidazole therapy for perianal Crohn's disease: a follow-up study. Gastroenterology 1982; 83: 383-7.
18. Turunen U, Farkkila M, Valtonen V, et al. Long-term outcome of ciprofloxacin treatment in severe perianal or fistulous Crohn's disease. Gastroenterology 1993; 104: A793 (Abstract).
19. Peppercorn MA. Is there a role for antibiotics as primary therapy in Crohn's ileitis? J Clin Gastroenterol 1993; 17: 235-7.
20. Prantera C, Kohn A, Zannoni F, et al. Metronidazole plus ciprofloxacin in the treatment of active, refractory Crohn's disease: results of an open study. J Clin Gastroenterol 1994; 19: 79-88.
21. Turunen U, Farkkila M, Hakala K, et al. Ciprofloxacin treatment combined with conventional therapy in Crohn's disease: a prospective, double blind, placebo controlled study. Gut 1995; 37: A193(Abstract).
22. Prantera C, Zannoni F, Scribano M-L, et al. An antibiotic regimen for the treatment of active Crohn's disease: a randomized, controlled clinical trial of metronidazole plus ciprofloxacin. Am J Gastroenterol 1996; 91: 328-32.
23. Colombel JF, Lemann M, Cassagnou M, et al. A controlled trial comparing ciprofloxacin with mesalazine for the treatment of active Crohn's disease. Am J Gastroenterol 1999; 94: 674-8.
24. Arnold GL, Patel H, Beaves M, Boyd H. Ciprofloxacin in Active Crohn's Disease, preliminary report of a 6 month randomized placebo controlled study. Gastroenterology 1999; 116: A664(Abstract).
25. Steinhart AH, Feagan BG, Greenberg GR, et al. Combined budesonide and antibiotic therapy for active Crohn's disease: a randomized controlled trial. Gastroenterology 2001; 120: A126(Abstract).
26. Prantera C, Berto E, Scribano ML, Falasco G. Use of antibiotics in the treatment of active Crohn's disease: experience with metronidazole and ciprofloxacin. Ital J Gastroenterol Hepatol 1998; 30: 602-6.
27. Allison MC, Pounder RE. Cyclosporin for Crohn's disease. Lancet 1984; i: 902.
28. Brynskov J, Freund L, Rasmussen SN, et al. A placebo-controlled, double-blind, randomized trial of cyclosporine therapy in active, chronic Crohn's disease. N Engl J Med 1989; 321: 845-50.
29. Jewell DP, Lennard-Jones JE, the Cyclosporin Study Group of Great Britain and Ireland. Oral cyclosporin for chronic active Crohn's disease: a multicentre controlled trial. Eur J Gastroenterol Hepatol 1994; 6: 499-505.
30. Feagan BG, McDonald JWD, Rochon J, et al. Low-dose cyclosporine for the treatment of Crohn's disease. N Engl J Med 1994; 330: 1846-51.
31. Stange EF, Modigliani R, Pena AS, et al. European trial of cyclosporin in chronic active Crohn's disease: a 12-month study. Gastroenterology 1995; 109: 774-82.
32. Burke JF, Pirsch JD, Ramos EL. Long-term efficacy and safety of cyclosporine in renal-transplant recipients. N Engl J Med 1994; 331: 358-63.
33. Kozarek PA, Patterson DJ, Gelfand MD, Botoman VA, Ball TJ, Wilske KR. Methotrexate induces clinical and histological remission in patients with refractory inflammatory bowel disease. Ann Intern Med 1989; 110: 353-6.
34. Feagan BG, Rochon J, Fedorak RN. Methotrexate for the treatment of Crohn's disease. N Engl J Med 1995; 332: 292-7.
35. Oren R, Moshkowitz M, Odes S. Methotrexate in chronic active Crohn's disease: a double-blind, randomized, Israeli multicenter trial. Am J Gastroenterol 1997; 92: 2203-9.
36. Breese EJ, Michie CA, Nicholls SW, et al. Tumor necrosis factor alpha-producing cells in the intestinal mucosa of children with inflammatory bowel disease. Gastroenterology 1994; 106: 1455-66.
37. van Dullemen HM, van Deventer SJH, Hommes DW, et al. Treatment of Crohn's disease with anti-tumor necrosis factor chimeric monoclonal antibody (cA2). Gastroenterology 1995; 109: 129-35.
38. Targan SR, Hanauer SB, van Deventer SJH, et al. A short-term study of chimeric monoclonal antibody cA2 to tumor necrosis factor α for Crohn's disease. N Engl J Med 1997; 337: 1029-35.
39. Rutgeerts P, D'Haens G, Targan S, et al. Efficacy and safety of retreatment with anti-tumor necrosis factor antibody (infliximab) to maintain remission in Crohn's disease. Gastroenterology 1999; 117: 761-9.
40. Present DH, Rutgeerts P, Targan S, et al. Infliximab for the treatment of fistulas in patients with Crohn's disease. N Engl J Med 1999; 340: 1398-405.
41. Hanauer SB, Feagan BC, Lichtenstein GR, et al. Maintenance infliximab for Crohn's disease: the ACCENT I randomised trial. Lancet 2002; 359: 1541-9.
42. Keane J, Gershon S, Wise RP, et al. Tuberculosis associated with infliximab, a tumor necrosis factor-α neutralizing agent. N Engl J Med 2001; 345(1098): 104.
43. Stack WA, Mann SD, Roy AJ, et al. Randomised controlled trial of CDP571 antibody to tumor necrosis factor-α in Crohn's disease. Lancet 1997; 349: 521-4.
44. Best WR, Becktel JM, Singleton JW, Kern F Jr. Development of Crohn's disease activity index. National Cooperative Crohn's Disease Study. Gastroenterology 1976; 70: 439-44.
45. Sandborn WJ, Feagan BG, Hanauer SB, et al. An engineered human antibody to TNF (CDP571) for active Crohn's disease: a randomized double-blind placebo-controlled trial. Gastroenterology 2001; 120: 1330-8.
46. D'Haens G, Swijsen C, Norman M, et al. Etanercept in the treatment of active refractory Crohn's disease: a single-center pilot trial. Am J Gastroenterol 2001; 96: 2564-8.
47. Sanborn WJ, Hanauer SB, Katz S, et al. Etanercept for active Crohn's disease: a randomized, double-blind, placebo-controlled trial. Gastroenterology 2001; 121: 1088-94.
48. Ehrenpreis ED, Kane SV, Cohen LB, Cohen RD, Hanauer SB. Thalidomide therapy for patients with refractory Crohn's disease: an open-label trial. Gastroenterology 1999; 117: 1271-7.
49. Vasiliauskas EA, Kam LY, Abreu-Martin MT, et al. An open-label pilot study of low-dose thalidomide in chronically active, steroid-dependent Crohn's disease. Gastroenterology 1999; 117: 1278-87.
50. Sabate JM, Villarejo J, Lemann M, Bonnet J, Allez M, Modigliani R. An open-label study of thalidomide for maintenance therapy in responders to infliximab in chronically active and fistulizing refractory Crohn's disease. Aliment Pharmacol Ther 2002; 16: 1117-24.
51. Gordon DH, Lai CWY, Hamilton MI, et al. A randomized placebo-controlled trial of a humanized monoclonal antibody to α4 integrin in active Crohn's disease. Gastroenterology 2001; 121: 268-74.
52. Van Deventer SJH, Elson CO, Fedorak RN. Multiple doses of intravenous interleukin 10 in steroid-refractory Crohn's disease. Gastroenterology 1997; 113: 383-9.
53. Schreiber S, Fedorak RN, Nilsen OH, et al. Safety d efficacy of recombinant human interleukin 10 in chronic active Cronh's disease. Gastroenterology 2000; 119: 1461-72.
54. Fedorak RN, Gangl A, Elson CO, et al. Recombinant human interleukin 10 in the treatment of patients with mild to moderately active Crohn's disease. Gastroenterology 2000; 119: 1473-82.
55. Sands BE, Bank S, Sninsky CA, et al. Preliminary evaluation of safety and activity of recombinant human interleukin 11 in patients with active Crohn's disease. Gastroenterology 1999; 117: 58-64.
56. Sands BE, Winston BD, Salzberg B, et al. Randomized, controlled trial of recombinant human interlekin-11 in patients with active Crohn's disease. Aliment Pharmacol Ther 2002; 16: 399-406.
57. Yacyshyn BR, Bowen-Yacyshyn MB, Jewell L, et al. A placebo-controlled trial of ICAM-1 antisense oligonucleotide in the treatment of Crohn's disease. Gastroenterology 1998; 114: 1133-42.
58. Schreiber S, Nikolaus S, Malchow H, et al. Absence of efficacy of subcutaneous antisense ICAM-1 treatment of chronic active Crohn's disease. Gastroenterology 2001; 120: 1339-46.
59. Yacyshin BR, Chey WY, Salzberg B, et al. Double blind, placebo controlled trial of the remission reducing and steroid sparing properties of an ICAM-1 antisense oligodeoxynucleotide, alicaforsen (ISIS 2302), in active steroid dependent Crohn's disease. Gut 2002; 51: 30-6.